New Delhi, June 8 -- Bharat Biotech International Ltd, which developed the covaxin vaccine to protect against earlier variants of covid-19, says its intranasal and injectable vaccine platforms are ready to be adapted for new strains of the disease.

India has recorded 5,755 active covid cases, according to the Union health ministry's data issued on Sunday. The nation also reported four new fatalities in the last 24 hours, taking the total covid death toll since 1 January to 59.

Health officials have identified two new JN.1 covid variants as the cause of the fresh wave of the infectious disease.

Suchrita Ella, managing director of Bharat Biotech, said the company's nasal vaccine iNCOVACC is "specifically designed for flexibility to adapt...